|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Egawa S, Toma H, Ohigashi H, Okusaka T,
Nakao A, Hatori T, Maguchi H, Yanagisawa A and Tanaka M: Japan
pancreatic cancer registry; 30th year anniversary: Japan pancreas
society. Pancreas. 41:985–992. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Matsuno S, Egawa S, Fukuyama S, Motoi F,
Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, et al:
Pancreatic cancer registry in Japan: 20 years of experience.
Pancreas. 28:219–230. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Winter JM, Cameron JL, Campbell KA, Arnold
MA, Chang DC, Coleman J, Hodgin MB, Sauter PK, Hruban RH, Riall TS,
et al: 1423 pancreaticoduodenectomies for pancreatic cancer: A
single-institution experience. J Gastrointest Surg. 10:1199–1210;
discussion 1210–1191. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Grobmyer SR, Pieracci FM, Allen PJ,
Brennan MF and Jaques DP: Defining morbidity after
pancreaticoduodenectomy: Use of a prospective complication grading
system. J Am Coll Surg. 204:356–364. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kimura H, Ohtsuka T, Matsunaga T, Watanabe
Y, Tamura K, Ideno N, Aso T, Miyazaki T, Osoegawa T, Aishima S, et
al: Predictors and diagnostic strategies for early-stage pancreatic
ductal adenocarcinoma: A retrospective study. Pancreas.
44:1148–1154. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Serrano PE, Cleary SP, Dhani N, Kim PT,
Greig PD, Leung K, Moulton CA, Gallinger S and Wei AC: Improved
long-term outcomes after resection of pancreatic adenocarcinoma: A
comparison between two time periods. Ann Surg Oncol. 22:1160–1167.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Garcea G, Dennison AR, Pattenden CJ, Neal
CP, Sutton CD and Berry DP: Survival following curative resection
for pancreatic ductal adenocarcinoma. A systematic review of the
literature. JOP. 9:99–132. 2008.PubMed/NCBI
|
|
9
|
Neoptolemos JP, Kleeff J, Michl P,
Costello E, Greenhalf W and Palmer DH: Therapeutic developments in
pancreatic cancer: Current and future perspectives. Nat Rev
Gastroenterol Hepatol. 15:333–348. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kleeff J, Korc M, Apte M, La Vecchia C,
Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH
and Neoptolemos JP: Pancreatic cancer. Nat Rev Dis Primers.
2:160222016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu Y, Guo X, Fan Y, Wang D, Wu W, Wu L,
Liu T, Xu B, Feng Y, Wang Y, et al: Efficacy and safety comparison
of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line
chemotherapy for metastatic pancreatic cancer. Jpn J Clin Oncol.
48:535–541. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sherman WH, Hecht E, Leung D and Chu K:
Predictors of response and survival in locally advanced
adenocarcinoma of the pancreas following neoadjuvant GTX with or
without radiation therapy. Oncologist. 23:4–e10. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jang JY, Han Y, Lee H, Kim SW, Kwon W, Lee
KH, Oh DY, Chie EK, Lee JM, Heo JS, et al: Oncological benefits of
neoadjuvant chemoradiation with gemcitabine versus upfront surgery
in patients with borderline resectable pancreatic cancer: A
prospective, randomized, open-label, multicenter phase 2/3 trial.
Ann Surg. 268:215–222. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yamada S, Fujii T, Sugimoto H, Nomoto S,
Takeda S, Kodera Y and Nakao A: Aggressive surgery for borderline
resectable pancreatic cancer: Evaluation of national comprehensive
cancer network guidelines. Pancreas. 42:1004–1010. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Isaji S, Mizuno S, Windsor JA, Bassi C,
Fernandez-Del Castillo C, Hackert T, Hayasaki A, Katz MHG, Kim SW,
Kishiwada M, et al: International consensus on definition and
criteria of borderline resectable pancreatic ductal adenocarcinoma
2017. Pancreatology. 18:2–11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ishikawa O, Ohigashi H, Imaoka S, Furukawa
H, Sasaki Y, Fujita M, Kuroda C and Iwanaga T: Preoperative
indications for extended pancreatectomy for locally advanced
pancreas cancer involving the portal vein. Ann Surg. 215:231–236.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Uchida K and Masugi Y: Histological
assessment of therapeutic response. Classification of Pancreatic
Carcinoma: Japan Pancreas Society. Isaji S: Kanehara & Co.,
Ltd.; Tokyo: pp. 117–122. 2017
|
|
19
|
Ushijima T, Okabe Y, Ishida Y, Sugiyama G,
Sasaki Y, Kuraoka K, Yasumoto M, Taira T, Naito Y, Nakayama M, et
al: Evaluation of endoscopic cytological diagnosis of unresectable
pancreatic cancer prior to and after the introduction of endoscopic
ultrasound-guided fine-needle aspiration. Mol Clin Oncol.
2:599–603. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nakama Y, Kawahara R, Nomura Y, Muroya D,
Arai S, Ishikawa H, Yasunaga M, Horiuchi H, Akagi Y, Tanaka H, et
al: A case of pancreatic head cancer showing pathological complete
response to neoadjuvant chemoradiation therapy. Gan To Kagaku
Ryoho. 42:2376–2378. 2015.(In Japanese). PubMed/NCBI
|
|
21
|
Ravikumar R, Sabin C, Abu Hilal M,
Bramhall S, White S, Wigmore S, Imber CJ and Fusai G; UK Vascular
Resection in Pancreatic Cancer Study Group, : Portal vein resection
in borderline resectable pancreatic cancer: A United Kingdom
multicenter study. J Am Coll Surg. 218:401–411. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yekebas EF, Bogoevski D, Cataldegirmen G,
Kunze C, Marx A, Vashist YK, Schurr PG, Liebl L, Thieltges S, Gawad
KA, et al: En bloc vascular resection for locally advanced
pancreatic malignancies infiltrating major blood vessels:
Perioperative outcome and long-term survival in 136 patients. Ann
Surg. 247:300–309. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tseng JF, Raut CP, Lee JE, Pisters PW,
Vauthey JN, Abdalla EK, Gomez HF, Sun CC, Crane CH, Wolff RA and
Evans DB: Pancreaticoduodenectomy with vascular resection: Margin
status and survival duration. J Gastrointest Surg. 8:935–949;
discussion 949–950. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Iacobuzio-Donahue CA, Fu B, Yachida S, Luo
M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P,
et al: DPC4 gene status of the primary carcinoma correlates with
patterns of failure in patients with pancreatic cancer. J Clin
Oncol. 27:1806–1813. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hamada Y and Nakayama Y: Aggressive venous
invasion in the area of carcinoma correlates with liver metastasis
as an index of metastasis for invasive ductal carcinoma of the
pancreas. Pancreatology. 17:951–955. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nagakawa Y, Aoki T, Kasuya K, Tsuchida A
and Koyanagi Y: Histologic features of venous invasion, expression
of vascular endothelial growth factor and matrix
metalloproteinase-2 and matrix metalloproteinase-9, and the
relation with liver metastasis in pancreatic cancer. Pancreas.
24:169–178. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Naito Y, Suda K, Nobukawa B, Kinoshita H
and Kojiro M: Histopathological study of invasive ductal carcinoma
(IDC) of the pancreas without associated cancerous occlusion of the
main pancreatic duct. J Hepatobiliary Pancreat Surg. 13:556–561.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yamasaki S, Suda K, Nobukawa B and Sonoue
H: Intraductal spread of pancreatic cancer. Clinicopathologic study
of 54 pancreatectomized patients. Pancreatology. 2:407–412. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chatterjee D, Katz MH, Rashid A,
Varadhachary GR, Wolff RA, Wang H, Lee JE, Pisters PW, Vauthey JN,
Crane C, et al: Histologic grading of the extent of residual
carcinoma following neoadjuvant chemoradiation in pancreatic ductal
adenocarcinoma: A predictor for patient outcome. Cancer.
118:3182–3190. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ajani JA, Mansfield PF, Crane CH, Wu TT,
Lunagomez S, Lynch PM, Janjan N, Feig B, Faust J, Yao JC, et al:
Paclitaxel-based chemoradiotherapy in localized gastric carcinoma:
Degree of pathologic response and not clinical parameters dictated
patient outcome. J Clin Oncol. 23:1237–1244. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu TT, Chirieac LR, Abraham SC, Krasinskas
AM, Wang H, Rashid A, Correa AM, Hofstetter WL, Ajani JA and
Swisher SG: Excellent interobserver agreement on grading the extent
of residual carcinoma after preoperative chemoradiation in
esophageal and esophagogastric junction carcinoma: A reliable
predictor for patient outcome. Am J Surg Pathol. 31:58–64. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ryan R, Gibbons D, Hyland JM, Treanor D,
White A, Mulcahy HE, O'Donoghue DP, Moriarty M, Fennelly D and
Sheahan K: Pathological response following long-course neoadjuvant
chemoradiotherapy for locally advanced rectal cancer.
Histopathology. 47:141–146. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh
Rde W, Collisson E, Schwartz L, Frankel W, Martin R, Conway W, et
al: Preoperative modified FOLFIRINOX treatment followed by
capecitabine-based chemoradiation for borderline resectable
pancreatic cancer: Alliance for clinical trials in oncology trial
A021101. JAMA Surg. 151:e1611372016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Okada KI, Hirono S, Kawai M, Miyazawa M,
Shimizu A, Kitahata Y, Ueno M, Hayami S and Yamaue H: Phase I study
of nab-paclitaxel plus gemcitabine as neoadjuvant therapy for
borderline resectable pancreatic cancer. Anticancer Res.
37:853–858. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Okada KI, Shimokawa T, Hirono S, Kawai M,
Sho M, Satoi S, Matsumoto I, Eguchi H, Murakami Y, Yamada S, et al:
Effect of neoadjuvant nab-paclitaxel plus gemcitabine therapy on
overall survival in patients with borderline resectable pancreatic
cancer: A prospective multicenter phase II trial (NAC-GA Trial).
Oncology. 93:343–346. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Von Hoff DD, Ramanathan RK, Borad MJ,
Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias
JL, et al: Gemcitabine plus nab-paclitaxel is an active regimen in
patients with advanced pancreatic cancer: A phase I/II trial. J
Clin Oncol. 29:4548–4554. 2011. View Article : Google Scholar
|
